Navigate Titan Pharmaceuticals, Inc.
Home
About
Overview
Management Team
Board of Directors
Careers
News
Overview
Press Releases
Events
Presentations
In the News
Media Resources
Investors
Overview
News / Events
Company Information
Stock Data
SEC Filings
Corporate Governance
Contact
Search
All SEC Filings
Home
Investors
SEC Filings
All SEC Filings
Investors
Navigate Investors
Overview
News / Events
Company Information
Stock Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Email Alerts
Tear Sheet
Contacts
RSS News Feed
All SEC Filings
Filter Filings:
View All
10-12G
10-12G/A
10-K
10-K/A
10-K405
10-Q
10-Q/A
10KSB40
10QSB
15-12B
25
3
3/A
4
4/A
424B2
424B3
424B4
424B5
425
8-A12B
8-A12B/A
8-A12G
8-K
8-K/A
ARS
AW
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DEFN14A
DEFR14A
DFAN14A
EFFECT
FWP
NT 10-Q
POS AM
PRE 14A
PREN14A
PRRN14A
REGDEX
RW
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-8
SB-2
SB-2/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
UPLOAD
Date
Form
Description
Docs
XBRL
Pages
10/28/20
8-K
Current report filing
Related Documents
EX-99.1
4
10/27/20
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Related Documents
EX-4.10
EX-4.11
72
10/26/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
10/26/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
10/26/20
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Related Documents
EX-4.10
EX-4.11
EX-23.1
68
10/26/20
8-K
Current report filing
Related Documents
EX-10.1
EX-99.1
22
10/23/20
PRE 14A
Preliminary proxy statement not related to a contested matter or merger/acquisition
11
10/22/20
UPLOAD
SEC-generated letter
Related Documents
TEXT-EXTRACT
1
10/19/20
S-1
General form of registration statement for all companies including face-amount certificate companies
Related Documents
EX-1.1
EX-4.10
EX-5.1
EX-23.1
110
10/15/20
8-K
Current report filing
Related Documents
EX-99.1
9
<< Previous
1...
14
15
16
17
18
19
20
21
22
23
...101
Next >>